drugset / Trial / NCT02112110
Absolute Bioavailability of BMS-791325
NaSingle-groupOpen-label
Summary
The purpose of this study is to determine the absolute bioavailability of 150 mg oral dose of BMS-791325 relative to 100 µg IV infusion of \[13C\]-BMS-791325.
Timeline
- Start
- 2014-04
- Primary completion
- 2014-05
- Completion
- 2014-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Beclabuvir | Small molecule | 150 mg | Oral |
| Subject | [13C]-BMS-791325 | Unknown | 100 ug | Intravenous |